 NEW YORK, June 21, 2021 PRNewswire -- Chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the 34.45 million IPO of Femasys, Inc. NASDAQ: FEMY a biomedical company focused on transforming womens healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. We are delighted to work with the outstanding team at Femasys in support of their commitment to womens healthcare, said Matthew Mrozinski, a partner in the investment banking group at Chardan. 